The U.S. Food and Drug Administration (FDA) granted a supplemental application approval for Opdivo (nivolumab) on 2020-05-26. This approval specifically pertains to the drug's efficacy, indicating an expansion of its demonstrated therapeutic benefits in a new or modified context.
Background
Opdivo (nivolumab) is an established immunotherapy, a programmed death-1 (PD-1) blocking antibody. It is widely used in the treatment of various cancers. Supplemental applications for approved drugs like nivolumab are typically submitted to the FDA to request approval for new indications, new patient populations, new dosing regimens, or other changes that expand the drug's approved uses. This particular supplemental approval focused on demonstrating additional efficacy for the drug, building upon its existing profile.
What this means
A supplemental approval for efficacy signifies that Opdivo (nivolumab) has met FDA standards for demonstrating clinical benefit in a new area of use. While the specific details of the new indication or patient population are not provided in this summary, such approvals are crucial for expanding treatment options for patients and for clinicians seeking to apply proven therapies to a broader range of clinical scenarios. Clinicians and researchers should consult the full FDA approval document for comprehensive information regarding the specific scope of this efficacy-based supplemental approval, including any new patient populations, indications, or dosing recommendations.
Source
This information is derived from the U.S. Food and Drug Administration (FDA) website, detailing a supplemental application approval (BLA 125554 S-82) for Opdivo (nivolumab). The approval was granted on 2020-05-26 and is accessible via accessdata.fda.gov.